Estudo dos marcadores cutâneos indicadores de risco para carcinoma basocelular

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)

Estudos imuno-histoquímico das proteínas p53, p16, Fhit, caspase 3 e antígeno Ki67 ; e citogenético molecular em lesões benignas e carcinoma de esôfago

Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)

Identificação e validação de genes diferencialmente expressos em carcinoma de pênis

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)

Studio di classi di sferoidi multicellulari di carcinoma polmonare epidermoidale in radiobiologia

Il tumore del polmone rappresenta la prima causa di morte nei paesi industrializzati. Le possibilità di trapianto ed intervento chirurgico risultano molto limitate pertanto lo standard di cura risulta essere la radioterapia, a volte abbinata alla chemioterapia. Sebbene trattando radioterapicamente il tumore si ottengano ottimi risultati, attualmente non esistono solide linee guida per la personalizzazione del trattamento al paziente. Il poter eseguire in laboratorio test radioterapici su un elevato numero di campioni risulterebbe un valido approccio sperimentale d’indagine, ma la carenza di materiale su cui poter condurre gli esperimenti limita questa possibilità. Tipicamente, per ovviare al problema vengono utilizzati sferoidi multicellulari tridimensionali creati in laboratorio partendo da singole cellule del tumore in esame. In particolare, l’efficacia del trattamento viene tipicamente correlata alla riduzione volumetrica media stimata utilizzando un set di sferoidi teoricamente identici. In questo studio vengono messe in discussione la validità delle affermazioni tipicamente sostenute attraverso l’analisi di volumi medi. Abbiamo utilizzando un set di circa 100 sferoidi creati in laboratorio partendo da singole cellule di carcinoma epidermoidale polmonare e trattati secondo sette differenti modalità di trattamento radioterapico (variando intensità di radiazione e numero di frazioni). In una prima fase abbiamo analizzato le singole immagini, acquisite al microscopio ottico circa ogni 48 ore, per identificare features morfometriche significative da affiancare all’analisi volumetrica. Sulla base dell’andamento temporale di queste features abbiamo suddiviso gli sferoidi in sottoclassi con evoluzioni completamente differenti che fanno supporre un differente “stato” biologico. Attraverso algoritmi di estrazione di features e classificazione e analizzando riduzione volumetrica, grado di frastagliatura del bordo e quantità di cellule liberate nel terreno di coltura abbiamo definito un protocollo per identificare in maniera automatica le sottopopolazioni di sferoidi. Infine, abbiamo ricercato con successo alcune features morfometriche in grado di predire, semplicemente analizzando immagini acquisite nei giorni seguenti all’ultimo trattamento, lo “stato di salute” del tumore a medio/lungo periodo. Gli algoritmi realizzati e le features identificate se opportunamente validate potrebbero risultare un importante strumento non invasivo di ausilio per il radioterapista per valutare nel breve periodo gli effetti a lungo periodo del trattamento e quindi poter modificare parametri di cura al fine di raggiungere uno stato desiderato del tumore.

Prospective, non-randomized phase 2 clinical trial of carboplatin plus paclitaxel with sequential radical pelvic radiotherapy for uterine papillary serous carcinoma

Objective Uterine Papillary Serous Carcinoma (UPSC) is uncommon and accounts for less than 5% of all uterine cancers. Therefore the majority of evidence about the benefits of adjuvant treatment comes from retrospective case series. We conducted a prospective multi-centre non-randomized phase 2 clinical trial using four cycles of adjuvant paclitaxel plus carboplatin chemotherapy followed by pelvic radiotherapy, in order to evaluate the tolerability and safety of this approach. Methods This trial enrolled patients with newly diagnosed, previously untreated patients with stage 1b-4 (FIGO-1988) UPSC with a papillary serous component of at least 30%. Paclitaxel (175 mg/m2) and carboplatin (AUC 6) were administered on day 1 of each 3-week cycle for 4 cycles. Chemotherapy was followed by external beam radiotherapy to the whole pelvis (50.4 Gy over 5.5 weeks). Completion and toxicity of treatment (Common Toxicity Criteria, CTC) and quality of life measures were the primary outcome indicators. Results Twenty-nine of 31 patients completed treatment as planned. Dose reduction was needed in 9 patients (29%), treatment delay in 7 (23%), and treatment cessation in 2 patients (6.5%). Hematologic toxicity, grade 3 or 4 occurred in 19% (6/31) of patients. Patients' self-reported quality of life remained stable throughout treatment. Thirteen of the 29 patients with stages 1–3 disease (44.8%) recurred (average follow up 28.1 months, range 8–60 months). Conclusion This multimodal treatment is feasible, safe and tolerated reasonably well and would be suitable for use in multi-institutional prospective randomized clinical trials incorporating novel therapies in patients with UPSC.

Correlation of the expression of human kallikrein-related peptidases 4 and 7 with the prognosis in oral squamous cell carcinoma

Background Very few articles have been written about the expression of kallikreins (KLK4 and KLK7) in oral cancers. Therefore, the purpose of this study was to examine and report on their prognostic potential. Methods Eighty archival blocks of primary oral cancers were sectioned and stained for KLK4 and KLK7 by immunohistochemistry. The percentage and the intensity of malignant keratinocyte staining were correlated with patient survival using Cox regression analysis. Results Both kallikreins were expressed strongly in the majority of tumor cells in 68 of 80 cases: these were mostly moderately or poorly differentiated neoplasms. Staining was particularly intense at the infiltrating front. Patients with intense staining had significantly shorter overall survival (p < .05). Conclusion This is the first observation on the patient survival influenced by kallikrein expression in oral carcinoma. The findings are consistent with those for carcinomas at other sites, in particular the prostate and ovary. KLK4 and/or KLK7 immunohistochemistry seems to have diagnostic and prognostic potential in this disease.

Epithelial—mesenchymal and mesenchymal—epithelial transitions in carcinoma progression

Like a set of bookends, cellular, molecular, and genetic changes of the beginnings of life mirror those of one of the most common cause of death—metastatic cancer. Epithelial to mesenchymal transition (EMT) is an important change in cell phenotype which allows the escape of epithelial cells from the structural constraints imposed by tissue architecture, and was first recognized by Elizabeth Hay in the early to mid 1980's to be a central process in early embryonic morphogenesis. Reversals of these changes, termed mesenchymal to epithelial transitions (METs), also occur and are important in tissue construction in normal development. Over the last decade, evidence has mounted for EMT as the means through which solid tissue epithelial cancers invade and metastasize. However, demonstrating this potentially rapid and transient process in vivo has proven difficult and data connecting the relevance of this process to tumor progression is still somewhat limited and controversial. Evidence for an important role of MET in the development of clinically overt metastases is starting to accumulate, and model systems have been developed. This review details recent advances in the knowledge of EMT as it occurs in breast development and carcinoma and prostate cancer progression, and highlights the role that MET plays in cancer metastasis. Finally, perspectives from a clinical and translational viewpoint are discussed

Long term survival following the detection of circulating tumour cells in head and neck squamous cell carcinoma

Background Techniques for detecting circulating tumor cells in the peripheral blood of patients with head and neck cancers may identify individuals likely to benefit from early systemic treatment. Methods Reconstruction experiments were used to optimise immunomagnetic enrichment and RT-PCR detection of circulating tumor cells using four markers (ELF3, CK19, EGFR and EphB4). This method was then tested in a pilot study using samples from 16 patients with advanced head and neck carcinomas. Results Seven patients were positive for circulating tumour cells both prior to and after surgery, 4 patients were positive prior to but not after surgery, 3 patients were positive after but not prior to surgery and 2 patients were negative. Two patients tested positive for circulating cells but there was no other evidence of tumor spread. Given this patient cohort had mostly advanced disease, as expected the detection of circulating tumour cells was not associated with significant differences in overall or disease free survival. Conclusion For the first time, we show that almost all patients with advanced head and neck cancers have circulating cells at the time of surgery. The clinical application of techniques for detection of spreading disease, such as the immunomagnetic enrichment RT-PCR analysis used in this study, should be explored further.